Drug Profile
AK 106 001616
Alternative Names: AK-106; AK106-001616Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Asahi Kasei
- Class Analgesics; Anti-inflammatories; Antirheumatics
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Japan
- 30 Jul 2015 Phase-II development for Rheumatoid arthritis is ongoing in Europe
- 30 Jul 2015 NDR project - Asahi Kissei, AR 2014 (pipeline of May 2014) - pII (overseas) for RA - http://www.asahi-kasei.co.jp/asahi/en/ir/annual/14en.pdf; no latest pipeline